Pfizer

Pfizer expands Cambridge Kendall Square research facility

Friday, July 24, 2015

Pfizer has expanded its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus.With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main St. in Kendall Square in Cambridge, Mass. This space will continue to house the R&D activities that relocated to the building in 2014, and will enable the consolidation of Pfizer’s three other leased spaces in Cambridge into the one campus.

[Read More]

Pfizer enrolls first patient in phase III sickle cell disease trial

Thursday, June 25, 2015

Pfizer has announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study—a phase III clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are 6 years of age or older.

[Read More]

Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

[Read More]

Syndax appoints Dr. Briggs Morrison CEO, Michael Metzger president and COO

Monday, June 15, 2015

Syndax Pharmaceuticals, a privately held oncology company based in Waltham, Mass., has announced that Briggs W. Morrison, M.D., is joining the company as CEO and a member of the board of directors, and Michael A. Metzger is joining the company as president and chief operating officer. Morrison joins Syndax from AstraZeneca, where he was executive vice president, global medicines development and chief medical officer. Metzger joins from Regado Biosciences, where he was president and CEO through the company’s strategic merger with Tobira Therapeutics.

[Read More]

Teva rebuts Mylan chairman’s letter

Wednesday, June 10, 2015

Erez Vigodman, Teva’s president and CEO, has responded to the June 1 letter by Mylan’s executive chairman Robert J. Coury. Vigodman addresses Courey’s accusations about Teva’s hostile takeover of Mylan and the lack of information available to stakeholders.

[Read More]

PatientsLikeMe appoints Jason Johnson executive vice president, head of R&D

Wednesday, May 27, 2015

PatientsLikeMe has appointed Jason Johnson, Ph.D., executive vice president and head of R&D. Johnson leads the company’s research, data science and informatics teams, which focus on analyzing and merging patient-reported and other data types to develop models of disease progression and generate new insights about disease, treatments and health. Johnson reports directly to CEO Martin Coulter.

[Read More]

The Global Drug-Lag Problem

Tuesday, May 26, 2015

The Pulse on Global Trials by Matthew Howes

For all the advancements in medical research, certain regions of the world still wait to benefit from timely access to new drugs.

[Read More]

PatientsLikeMe appoints Jason Johnson executive vice president and head of R&D

Thursday, May 21, 2015

PatientsLikeMe has appointed Jason Johnson, Ph.D., as executive vice president and head of R&D. Johnson leads the company’s research, data science and informatics teams, which focus on analyzing and merging patient-reported and other data types to develop models of disease progression and generate new insights about disease, treatments and health. Johnson reports directly to CEO Martin Coulter.

[Read More]